Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4

• Published in: Journal of the American College of Cardiology Vol. 77; no. 12; p. 1576
• Main Authors: Tsimikas, Sotirios, Moriarty, Patrick M, Stroes, Erik S
• Format: Journal Article
• Language: English
• Published: United States 30.03.2021
• Subjects: cardiovascular disease; aortic stenosis; lipoprotein(a); lipoproteins; antisense
• ISSN: 1558-3597; 1558-3597
• DOI: 10.1016/j.jacc.2021.01.051

Lipoprotein(a) [Lp(a)] has risen to the level of an accepted cardiovascular disease risk factor, but final proof of causality awaits a randomized trial of Lp(a) lowering. Inhibiting apolipoprotein(a) production in the hepatocyte with ribonucleic acid therapeutics has emerged as an elegant and effective solution to reduce plasma Lp(a) levels. Phase 2 clinical trials have shown that the antisense oligonucleotide pelacarsen reduced mean Lp(a) levels by 80%, allowing 98% of subjects to reach on-treatment levels of <125 nmol/l (∼50 mg/dl). The phase 3 Lp(a)HORIZON (Assessing the Impact of Lipoprotein(a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD) outcomes trial is currently enrolling approximately 7,680 patients with history of myocardial infarction, ischemic stroke, and symptomatic peripheral arterial disease and controlled low-density lipoprotein cholesterol to pelacarsen versus placebo. The co-primary endpoints are major adverse cardiovascular events in subjects with Lp(a) >70 mg/dl and >90 mg/dl, in which either of the two being positive will lead to a successful trial. Additional ribonucleic acid-targeted therapies to lower Lp(a) are in preclinical and clinical development. The testing of the Lp(a) hypothesis will provide proof whether Lp(a)-mediated risk can be abolished by potent Lp(a) lowering.